Please assess the completion status of the following clinical trial:

Trial Title: Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 1 diabetes mellitus included in the phase II therapeutic trial with a humanized non-mitogenic CD3 monoclonal antibody (ChAgly CD3) at time of clinical diagnosis and who agree and are likely to comply with the investigator's instructions~Exclusion Criteria:~* Any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the patient~* Use of illicit drugs or over consumption of alcohol (\> 3 beers/day)~* Being legally incapacitated, having significant emotional problems at the time of the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: PLACEBO_COMPARATOR): None
- A (Type: ACTIVE_COMPARATOR): ChAgly CD3

Based on this trial design, predict the completion outcome and termination type (if applicable).